Chairman of PTC Board of Directors

Designee of Credit Suisse First Boston Equity Partners
Michael Schmertzler has served as a member of PTC's board of directors since August 2001 and as chairman of the board since November 2004. Since 2001, Mr. Schmertzler has been a managing director of Aries Advisors, LLC, the sub-advisor to Credit Suisse First Boston Equity Partners, L.P., a private equity fund, and the chair of the investment committee. Mr. Schmertzler is also currently the Chief Executive Officer of Kolltan Pharmaceuticals, an early stage company developing oncology therapeutics. From 1997 to 2001, Mr. Schmertzler was co-head of United States and Canadian Private Equity at Credit Suisse First Boston. Prior to 1997, Mr. Schmertzler held various management positions at Morgan Stanley and its affiliates, including president of the Morgan Stanley Leveraged Capital Funds and managing director and founder of the firm’s emerging pharmaceuticals investment banking business. Prior to Morgan Stanley he was a managing director, Chief Financial Officer and head of International Investment Banking, Sales and Trading of Lehman Brothers Kuhn Loeb and successor companies. Mr. Schmertzler is also director of Cytokinetics, Incorporated. Since 1978, he has been an Adjunct Professor and Lecturer at Yale University. Mr. Schmertzler received a B.A. from Yale College in Molecular Biophysics and Biochemistry, History and City Planning and an M.B.A. from the Harvard Business School.